Introduction
Clinical trials of therapies for acute coronary syndrome (ACS) such as coronary reperfusion and secondary prevention medicines such as statins have demonstrated effectiveness even in the oldest patients 1, 2 -however, this age group is less likely to receive both. 3 -5 Such older patients may have increased co-morbidity 6 and higher risk of complications from more intensive management 7 and thus this under-treatment relative to younger patients may be appropriate. As the population ages and the older age group becomes an increasingly larger proportion of the population, it is important to understand what effect intensive management is having on outcomes in these older patients, and what other additional factors impact on outcomes.
Trial evidence on best practice in the older patient with ACS may not represent the real-world older ACS patient with multiple comorbidities. The proportional representation in clinical trial populations of older patients is much lower (around 9%) than the real-world picture of the acute medical take, 8 where 35% patients are aged 75 or over. 9 There is a need for evidence from real-world data that more accurately depicts both receipt of treatment and outcomes in the older patient with ACS. Large clinical registries offer representative study populations with high generalizability, and importantly the statistical power to answer such questions. Using the Myocardial Ischaemia National Audit Project (MINAP), a national registry which contains data from patients with an ACS admitted to all 230 National Health Service (NHS) hospital trusts in England and Wales, 10 we aimed to explore the relationship of age group with receipt of more intensive management and secondary prevention medicine. Then we aimed to compare the association of intensive management on time to death over a conservative strategy by age group, seeking to account for any differences in survival through adjustment for co-morbidities, standards of care and disease severity, and the interaction of age group with management strategy.
Methods

Study design
This was a cohort study of patients admitted to hospital with ACS and followed up for all-cause mortality. MINAP was set-up in 1999 to examine the quality of management of acute myocardial infarction in England and Wales and to meet the audit requirements of the National Service Framework for Coronary Heart Disease. 11, 12 
Cohort profile
In this article, we used data pertaining to all patients from 2006 to 2010 (the most recent download of data with at least 1-year follow-up for allcause mortality). We analysed records of admissions between 1 January 2006 and 31 December 2010 for patients having a final diagnosis of ST-segment elevation myocardial infarction (STEMI) or of non-STsegment elevation myocardial infarction (NSTEMI). The final diagnosis was formed from the history, clinical examination, and results of inpatient investigations and was made by a senior member of the medical staff. Data were further extensively cleaned by us using a priori definitions and a data usage manual written. We further validated variables using cross-checks with other data fields-for instance, final diagnosis correlated well with elevated markers for STEMI and NSTEMI categories. The original data set consisted of 363 098 participants with a final diagnosis of STEMI or NSTEMI (ACS with a positive troponin blood test). Of these, 11 222 were dropped as 1-year follow-up status was unknown as were 431 aged under 18 with missing or impossibly high values (.111) for age. A further 3729 exclusions included those for whom the census date (at which patients' 1-year follow-up survival status was recorded) preceded the date of hospital admission and those in whom survival status was recorded before an entire year had passed since admission. Following these exclusions, there remained 347 716 observations in the data set, that is 96% of the original data set. The data set on which the analyses in this article are based consists of 155 818 subjects on whom a complete set of explanatory variables was available. Previous published imputation analyses on the MINAP data set by the lead author 14 have not significantly altered effect sizes and imply that missingness in MINAP is at random, while work by others has also shown that the level of missingness of data in MINAP does not alter regional standardized mortality ratios. 15 
Study variables
We measured secondary prevention medicine therapy usage by examining receipt of aspirin, ACE inhibitor, or statin on discharge. With regards to more intensive management, in patients with STEMI this referred to receipt of reperfusion available locally at the time of presentation (i.e. receipt of thrombolysis or primary percutaneous coronary intervention (PPCI))-centres increasingly shifted to PPCI over the course of the cohort and thus the strongest determinant of receipt of either of these treatments was local availability not age). In patients with NSTEMI, we regarded more intensive management as receipt of angiography in hospital, as previous work in MINAP has shown that any disparity in revascularization is driven primarily by less frequent referral for diagnostic angiogram. 16 The conservative group was defined as those who did not receive reperfusion in STEMI patients and those who did not receive angiography in NSTEMI patients. These group assignments of intensive management and conservative management were defined from the clinical management data as recorded by the MINAP clinical audit staff which outlined which treatment modalities each patient had undergone in hospital. For survival Cox regression analyses, the outcome was all-cause death. Markers of disease severity were collected as in-hospital clinical events of re-infarction, significant bleeding (any bleed as recorded by the clinician as well as retroperitoneal and intracranial haemorrhage), cardiac arrest, and abnormal ECG (e.g. ST or T wave changes or left bundle branch block). Co-morbid conditions were chronic renal failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, and congestive cardiac failure, while cardiovascular risk factors were smoking (ex or current), known diabetes mellitus, and known hypertension (definitions for variables are pre-defined by MINAP and given in Supplementary material online, Appendix S1). To account for potential regional differences in care, we used MINAP data on the patient's Strategic Health Authority, the regional body that oversees the provision of healthcare across a given region within the National Health Service of England and Wales.
Statistical analysis
We examined patient characteristics for the whole ACS cohort by age group (years) at presentation categorized as younger (18 to ,65), young -old (65 to ,75), old -old (75 to ,85), and oldest old (≥85) in line with previous work. 17 We applied logistic regression analyses separately for STEMI and NSTEMI patients to compare the odds of receipt of treatments for ACS against not receiving them-in turn for intensive management, aspirin, ACE inhibitor, or statin, and by age group using the youngest age group as the reference group on plots. We used the Chi-squared test to assess for trends by age.
To investigate whether the association of intensive management on time to death within a year of admission compared with the conservative group differed by age group, we constructed Cox proportional hazards regression models stratified by age group for STEMI and then NSTEMI, using intensive management as the reference group. Logistic regression of the whole cohort identified variables that independently contributed to mortality in order to build the Cox models. After crude estimates, we in turn adjusted for cardiovascular risk factors, co-morbidities, healthcare factors (receipt of secondary prevention and if under the care of a cardiologist rather than a generalist), and case severity variables (re-infarction, bleeding, cardiac arrest, and abnormal ECG), including sex in all these models before building a fully-adjusted combined model. Regression models included Hubert-White robust adjustment for intra-cluster correlation of outcomes within Strategic Health Authorities.
The interactions between the age and management strategy on time to death were evaluated separately for both STEMI and NSTEMI using a fully adjusted model with an interaction terms between age group and management strategy. We also examined age -treatment interactions within the full model with age modelled as a continuous instead of an ordered categorical variable. Wald tests were used to test the significance of age -treatment interaction.
Analyses were performed using Stata SE, version 11 (Stata, College Station, TX, USA).
Results
The records of 155 818 patients with complete data were examined. Of these, 103 540 (66.5%) were men. The mean age of the cohort was 69 (SD 14). The mean follow-up was 2.29 years (SD 1.42). Our final data set consisted of 68 025 STEMI and 87 793 NSTEMI patients. Patients' baseline characteristics by age group are shown in Table 1 for the whole ACS cohort. Younger patients were more likely to be men and smokers than older patients. Prevalence of hypertension rose with age though dyslipidaemia fell. Past history of coronary disease and co-morbidities rose with age, while receipt of previous coronary revascularization decreased with older age and patients who were older were less likely to have been cared for by a cardiologist during their admission with an ACS.
Receipt of management in hospital
With older age, patients were less likely to receive secondary prevention medicines and intensive management for both STEMI ( Figure 1 ) and NSTEMI ( Figure 2 Association of older age on adjusted time to death by receipt of intensive management
The association of intensive management on time to death over conservative management was examined by age strata. In all age groups of patients with STEMI, not receiving reperfusion was associated with worse unadjusted survival ( Table 2 ). The benefit of this intensive management strategy was attenuated in older patients as the hazard ratios (HRs) decrementally approached the reference category with older age groups. After adjusting for sex, further adjusting the HRs in separate models (Supplementary material online, Table S1 ) for cardiovascular risk factors and then for co-morbidities did not alter these results, though when adjusting for healthcare factors (receipt of secondary prevention and care by a cardiologist), the adverse prognosis associated with not receiving reperfusion was attenuated markedly in the oldest age group [HR 1.34 (1.24, 1.44)]. Adjusting for factors contributing to worse case severity (in-hospital cardiac arrest, in-hospital, re-infarction, abnormal ECG, in-hospital bleeding) did not alter these results in any age group. A fully adjusted model ( Table 2 ) attenuated the worse prognosis in those who did not undergo reperfusion in all age groups, in particular for the oldest age group with the effect size changing from 1.64 to 1.36, though this is likely to be driven mostly by adjustment for healthcare factors. Further accounting for clustering by Strategic Health Authority within the fully adjusted model did not change the point estimates (Supplementary material online, Table S1 ).
In patients with NSTEMI, conservative management was associated with worse unadjusted survival ( Table 3 ) in all age groups, but again the benefit of an intensive management strategy was attenuated in older patients as the HRs decrementally approached the reference category with older age groups. Adjustment for comorbidities, healthcare factors, and worse case severity (Supplementary material online, Table S2 ) did not significantly alter the results for any age group, nor did accounting for clustering by Strategic Health Authority within the fully adjusted model.
The interaction of age and receipt of intensive investigation
For both STEMI and NSTEMI, the fully adjusted Cox model showed an interaction between age group and receipt of intensive investigation (P , 0.001 for both). In NSTEMI, there was a reduced benefit from receiving intensive management with older age groups (final column of Table 3) , with those undergoing a conservative management strategy aged 85 or over having a HR of 1.90 (1.77, 2.04) when compared with those undergoing intensive management, with the comparable risk of death from a conservative approach being much higher HR 4.37 (4.00, 4.78) in those aged 18 to ,65. This pattern replicated with STEMI to a lesser extent (final column of Table 2 ).
Modelling age as a continuous variable, the adjusted hazards ratios for age -treatment interaction were 0.989 (0.985-0.992, P , 0.001) for STEMI and 0.969 (0.967-0.972, P , 0.001) for NSTEMI for each extra year of age-thus the increased HRs associated with conservative management were reduced by 0.989 and 0.969, respectively, for STEMI and NSTEMI for each extra year of age.
Discussion
We found an incremental reduction in the use of evidence-based therapies-both medicine-based and intensive-with increasing age using a national ACS registry cohort that reflects real-world clinical practice in England and Wales and that enabled categorization of ACS patients into STEMI and NSTEMI. We also found that improved survival was associated with intensive management at all ages, though the difference in survival benefit between it and a conservative strategy reduced incrementally with older age. Furthermore, we show that receipt of secondary prevention and care by a cardiologist might be of significant benefit in older patients with STEMI in reducing death within 1 year.
Our work correlates with the 2009 UK Department of Health commissioned report carried out by the Centre for Policy on Ageing which revealed clear and widespread evidence of age discrimination in hospital-based acute investigation and treatment of heart disease and in the subsequent instigation of secondary prevention regimes to be carried forward to the community following discharge. 18 Despite international guidelines 19 reminding clinicians that intensive management in the older patients with ACS is as effective as in their younger counterparts, we in line with other studies 17, 20 show that older patients are less likely to receive them. We add to this literature by using outcomes out to 1 year and thus presenting a population in which the sickest (who often die in hospital) are less influential in the data and which allows clinicians more scope to influence prognosis. We also distinguish between the two very different phenotypes that are STEMI and NSTEMI, undertake full adjustment for a wide range of prognostic factors within clinically relevant models, and use a large nationwide registry cohort study highly representative of the real-world ACS population. Then importantly, we sought to demonstrate which factors might influence longer-term mortality in different age groups in order to facilitate clinical decisionmaking in management. We suggest that an increasing usage of secondary prevention medicine therapy and specialist cardiologist input could account for the better outcomes increasingly seen in older patients with ACS-previous work in MINAP has revealed incremental reductions in short-term (in-hospital) mortality from 2003 to 2010 across all age groups including the oldest old. 17 Our work here also confirms ideas from others that improvements in hospital care for older patients would reduce mortality rates and that this might be achieved through the application of evidence-based ACS therapies to patients regardless of age.
21,22
The relative under-treatment of older patients with ACS may be down to a perception on the part of the clinician of a higher risk in older patients from intensive management, previous analyses in a subset of MINAP (using only those hospitals with interventional facilities) have shown that although co-morbidities are associated with higher mortality, the presence of co-morbidities do not significantly diminish the impact of intensive management on long-term mortality. 16 Though bleeding was more common with older age, the prevalence of such side effects in our work was low even in those aged 85 and over [2.9% had a significant in-hospital bleed and in those undergoing reperfusion only 0.84% of this oldest age group had an intracranial bleed compared with 0.2% of those aged 18 -64 (data not shown)]. A single-centre study from a hospital with interventional facilities also suggested that the lesser treatment in older patients Outcomes of ACS with older age cannot be explained by the nature of the healthcare facility they are admitted to. 23 On reviewing the literature on clinical trials of an intensive strategy in the older patient, these trial patients remain highly selected 24 and there remains a general dearth of clinical trial data in older patients. 25 The reduced benefits with older age of intensive management may be due to the higher risk of dying from ACS afforded by older age alone (as observed by around a half of patients aged 85 years and over in the conservative groups dying within a year), 26 while those youngest patients who do not undergo intensive management must have good reason not to-such as life-threatening clinical presentations or serious co-morbidity-thus widening the relative benefit between intervening intensively or not. Our separate models adjusting for potential confounding factors attempted to control for this but were unable to fully explain the survival differences between conservative and intensive management strategies. We included patients who died in hospital for these analyses to render this article applicable to clinicians who have to make What we cannot conclude from this article is the appropriateness for intensive management in the older patient with ACS. It is likely that clinicians are already applying clinical judgement in selecting patients for an intensive management strategy, and appropriately not intensively managing those patients that are frail, or have extensive co-morbidity. To a degree thus, the under-management we see in the older age groups here may be entirely reasonable but without a randomized controlled clinical trial design in all-comer older patients with ACS, criteria for selection for an intensive management strategy will remain unclear. Certainly, data from other registries suggest that older patients potentially stand to gain the most from an intensive management strategy due to their overall highest risk, consistent with the substantial impact of age on risk in scores such as the GRACE score. 20 However, selection of older patients for an intensive management strategy in the real world remains highly variable and they tend to be sicker and have more co-morbidities than those recruited in a trial. 27 Even if a trial were planned, it would be unethical to randomize all older patients to either strategy as-from clinical trial evidence on highly selected older patients-we know that an intensive strategy does work in those selected groups, and thus no such trial exists to this day. Any trial in this area would hence need to recruit and randomize those older patients in whom there was reasonable doubt as to the benefit of an intensive strategy in light of possible harm from such a strategy. What constitutes 'reasonable doubt' is, however, itself far from clear. Teasing out biological age from chronological age is perhaps key to this through the judicious use of a wider range of prognostic measures to guide the clinician as to the appropriateness of intensive management following presentation with ACS. Frailty is estimated to be present in more than 25% in those aged 85 and older 28 and some single-item measures (e.g. gait speed measured as 15-foot walk time with usual assistive device during the walk) are independently associated with mortality risk over follow-up as short as 6 months in an older population with coronary disease 29 -such measures are feasible in older patients in a clinical trial context 30 and may provide supplemental and useful information for clinical discussions about treatment risks and benefits.
Strengths and limitations
The strength of MINAP is its large size, representativeness and that it contains extensive data on clinical management and characterization. MINAP importantly allowed us to take into account the heterogeneity of ACS, as considerable differences exist in the pathology and subsequent management of a STEMI compared with a NSTEMI. Though it collects data from all 230 hospitals in England and Wales, MINAP cannot collect data on every patient with an ACS and it is possible that patients entered into the MINAP database differ from those not recorded, and that there may be differences in missingness by age. However, older and frailer patients with non-specific symptoms may be less likely to be included in registry data and therefore the magnitude of the relationships we observed may represent an underestimation. Regarding missing data, some fields were more problematic in this regards-in particular, clopidrogrel usage was missing in around half of patients and thus could not be used-and which reflects the fact that MINAP is an on-going audit-driven data set that describes evolving healthcare. As iterated above in this article, missingness is not thought to be a major concern in the validity of analyses within MINAP. Future work using MINAP in England may be strengthened through the linkage of electronic health records available in the Clinical Practice Research Datalink (www.cprd.com) and data on hospital admissions from Hospital Episode Statistics. 31 MINAP also lacks data on more detailed clinical measures [e.g. acute angiographic findings, presence of acute heart failure (thus not allowing us a calculation of a GRACE score 32 ), echocardiographic, or angiographic measurement of ventricular function etc.], the actual time of the angiogram and cause of death. It also did not have data on cognition, extreme frailty nor patient choice, and its comorbidity data were limited (e.g. no data on cancer)-thus we were unable to explore in greater detail reasons underlying the differences in receipt of care by age group, and on survival.
We also were unable to assess accurately the impact of older age on time from onset of symptoms to arrival within MINAP, and the relationship between in-hospital death and receipt of either management strategy-however, less than 5% of patients with ACS were considered to have had a delay in getting to hospital and of these less than 1% were delays associated with transfer, and less than 3% of patients (and less than 5% of patients aged 75 -84) died in hospital. Finally, as an ongoing audit-driven data set, MINAP spans evolving healthcare trends and our data covered the period in which reperfusion was moving from thrombolysis to PPCI. We combined these fields as if we were to exclude patients that had fibrinolysis, this exclusion would have been driven not by their appropriateness for fibrinolysis over PPCI but simply because at the time of their admission, their hospital could not offer PPCI. Equally, splitting the STEMI group into fibrinolysis and PPCI would not provide a meaningful analysis as the selection would simply be driven by the institution at which they were admitted to rather than being a clinically meaningful grouping. That fibrinolysis and PPCI are different treatments is less important when compared with the fact that they are both tools for reperfusion. By clearly splitting all the cohort analyses into STEMI (in whom the decision to reperfuse is made immediately) and NSTEMI (in whom patients are considered for an intensive strategy sometime later in the hospital), we have kept these two different ACS phenotypes and their specific management pathways separate.
Conclusions
We found an incremental reduction in the use of evidence-based therapies for ACS with older age in the national registry cohort for England and Wales and that better survival was associated with intensive management at all ages, though this benefit was attenuated the older the patient. Whether the optimal benefit could be achievable by a multidisciplinary care model with active involvement of cardiologists in the oldest old requires further evaluation in a clinical trial setting. 
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